We test your drugs on representative target cells
Our commitment is to test the pharmaceutical efficacy of drugs on innovative preclinical models representing systemic cancer disease.
We offer our clients the expertise in generating cellular models for functional analysis of rare cancer cell populations from fluids, organs, and primary tumors. Therefore, we have established technologies allowing expansion of few disseminated or circulating cancer cells despite their extremely low abundance. Such preclinical models based on rare cancer cells provide the opportunity to comparatively test drugs on cancer subpopulations mediating therapy resistance and consequently a relapse of the disease. Our expertise covers the performance of individualized pharmaceutical drug tests to analyze efficacy on target cells of systemic therapy both in vitro and in vivo.